Over the last 15 years, Dr. Mazziotti has carried out seminal studies in the field of bone and mineral metabolism with significant contributions in the knowledge of mechanisms and clinical presentation of skeletal fragility induced by endocrine diseases and endocrine therapies in oncological patients.
Two of the main accomplishments of the researches in the bone field were: 1) the application for the first time of vertebral morphometry for diagnosis of skeletal fragility in patients with osteoporosis related to endocrine disease; 2) the demonstration in humans that pituitary hormones (i.e., thyrotropin and prolactin) may have direct effects on bone and they may directly influence skeletal fragility.
Gherardo Mazziotti was also leader author of studies on glucocorticoid-induced osteoporosis and multicenter studies in the oncology field investigating the management of bone metastases from thyroid cancer and the efficacy and safety of non conventional therapeutic schedules in acromegaly. Dr. Mazziotti has published more than 200 papers in international peer-reviewed journals (more than 8600 citations, Scopus H-index 52; Scopus ID 6701486206).